3SBio Inc. has made waves in the biotechnology sector with its impressive 2025 annual results, showcasing how innovative research and global partnerships can bolster financial success. As a leading player in the industry, 3SBio’s annual revenue reached a remarkable RMB 17.7 billion, signifying a 94.3% year-on-year increase that surpasses the RMB 10 billion milestone. The company also reported a staggering net profit attributable to shareholders of RMB 8.48 billion, marking a 305.8% surge compared to the previous year. These figures highlight not just growth in revenue but also significant improvements in profitability, underscoring 3SBio’s strong market position.
Strategic R&D Investment Fuels Growth
In 2025, 3SBio allocated RMB 1.52 billion towards research and development, reflecting a 14.6% increase from the previous year. This investment serves as a cornerstone for advancing its innovative drug pipeline, ensuring that the company remains at the forefront of biopharmaceutical development. By the end of the year, the company’s total financial resources had ballooned to RMB 20.4 billion, supported by a reduced interest-bearing debt ratio of 9.8%. The financial structure not only showcases stability but also positions the company for sustained long-term growth.
Record-Breaking Collaboration with Pfizer
A landmark achievement for 3SBio in 2025 was its global licensing collaboration with Pfizer, centered around its proprietary PD-1/VEGF bispecific antibody, SSGJ-707. The deal, valued at over US$6 billion, included an unprecedented upfront payment of US$1.4 billion, setting a new record for a single out-licensing transaction of a Chinese innovative drug. This collaboration signifies international recognition of the high standards and quality inherent in Chinese biopharmaceutical innovation, while also enhancing 3SBio’s global competitiveness.
Under the agreement, 3SBio retains the rights to supply SSGJ-707’s bulk drug substance for clinical and commercial use in China and beyond. The initial delivery of this substance for global clinical development marks a crucial step in progressing towards commercialization. With nine international multi-center clinical trials already launched, the collaboration is on a fast track to explore various cancer indications, further unlocking the product’s potential.
Accelerating Innovation with New Drug Approvals
The year 2025 was pivotal for 3SBio as it celebrated a series of product approvals. Three novel drugs were launched, while existing core products received new indication approvals, including TPIAO®, which gained recognition for treating chronic liver disease-related thrombocytopenia. This approval not only expands treatment options but also solidifies the product’s status in the market.
In addition, Liporaxel®, an oral solution for advanced gastric cancer, received authoritative endorsement by being included in the CSCO Guidelines and the National Reimbursement Drug List. This innovative approach shifts treatment from hospital settings to home, enhancing patient convenience and adherence, and further broadening its market appeal.
Building a Robust Pipeline for Future Growth
3SBio’s commitment to innovation is evident in its diverse pipeline across various therapeutic areas, including hematology, oncology, autoimmune diseases, and nephrology. With multiple products in the New Drug Application (NDA) stage, the company is poised for abundant follow-up growth.
The biopharmaceutical landscape in China is evolving, with national policies promoting the sector’s transition from manufacturing to innovation-led advancement. 3SBio aims to leverage its three decades of industry experience to enhance its competitive edge in key areas such as bispecific and trispecific antibodies.
Commitment to Accessible Innovation
As 3SBio looks to the future, the company remains steadfast in its mission to make innovative biopharmaceuticals accessible to all. By investing in cutting-edge research and maintaining a robust pipeline, 3SBio is determined to bring high-quality drugs to market swiftly, thus positively impacting patients worldwide. With its strong financial foundation and commitment to integrity and innovation, the company is well-positioned to navigate the evolving landscape of the biopharmaceutical industry.
Key Takeaways
- 3SBio reported a remarkable RMB 17.7 billion in annual revenue for 2025, a 94.3% year-on-year increase.
- The company’s collaboration with Pfizer for SSGJ-707 set a record for the highest upfront payment in a Chinese drug out-licensing deal.
-
Multiple new drug approvals have expanded treatment options and market penetration for 3SBio’s core products.
-
3SBio is committed to enhancing its R&D pipeline and increasing accessibility to innovative therapies.
In summary, 3SBio’s annual results for 2025 reflect a powerful synergy of innovation and collaboration, solidifying its status as a leader in the biopharmaceutical field. The company’s proactive approach to R&D and strong financial performance are indicative of its potential for continued success and growth in the years to come.
Read more → www.manilatimes.net